

STARS Is Essential to Maintain Cardiac Development and Function *In Vivo* via a SRF Pathway

Nelson W. Chong^{1*}, Andrea L. Koekemoer¹, Samir Ounzain¹, Nilesh J. Samani¹, Jordan T. Shin², Stanley Y. Shaw^{3,4}

1 Department of Cardiovascular Sciences, Glenfield Hospital, Clinical Sciences Wing, University of Leicester, Leicester, United Kingdom, **2** Cardiology Division, Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, United States of America, **3** Center for Systems Biology, Simches Research Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America, **4** Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America

Abstract

Background: STARS (STriated muscle Activator of Rho Signaling) is a sarcomeric protein expressed early in cardiac development that acts as an acute stress sensor for pathological remodeling. However the role of STARS in cardiac development and function is incompletely understood. Here, we investigated the role of STARS in heart development and function in the zebrafish model and *in vitro*.

Methodology and Principal Findings: Expression of zebrafish STARS (*zSTARS*) first occurs in the somites by the 16 somite stage [17 hours post fertilization (hpf)]. *zSTARS* is expressed in both chambers of the heart by 48 hpf, and also in the developing brain, jaw structures and pectoral fins. Morpholino-induced knockdown of *zSTARS* alters atrial and ventricular dimensions and decreases ventricular fractional shortening (measured by high-speed video microscopy), with pericardial edema and decreased or absent circulation [abnormal cardiac phenotypes in 126/164 (77%) of morpholino-injected embryos vs. 0/152 (0%) of control morpholino embryos]. Co-injection of *zsrfl* (serum response factor) mRNA rescues the cardiac phenotype of *zSTARS* knockdown, resulting in improved fractional shortening and ventricular end-diastolic dimensions. Ectopic over-expression of STARS *in vitro* activates the STARS proximal promoter, which contains a conserved SRF site. Chromatin immunoprecipitation demonstrates that SRF binds to this site *in vivo* and the SRF inhibitor CCG-1423 completely blocks STARS proximal reporter activity in H9c2 cells.

Conclusions/Significance: This study demonstrates for the first time that STARS deficiency severely disrupts cardiac development and function *in vivo* and revealed a novel STARS-SRF feed-forward autoregulatory loop that could play an essential role in STARS regulation and cardiac function.

Citation: Chong NW, Koekemoer AL, Ounzain S, Samani NJ, Shin JT, et al. (2012) STARS Is Essential to Maintain Cardiac Development and Function *In Vivo* via a SRF Pathway. PLoS ONE 7(7): e40966. doi:10.1371/journal.pone.0040966

Editor: Rakesh Kukreja, Virginia Commonwealth University Medical Center, United States of America

Received: November 8, 2011; **Accepted:** June 18, 2012; **Published:** July 18, 2012

Copyright: © 2012 Chong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by National Institutes of Health/National Heart, Lung, and Blood Institute K08 HL077186 (S.Y.S.), HL-085280 (J.T.S.) and the Heart Research UK (RG2474/04/07; N.W.C.). N.J.S. holds a British Heart Foundation Chair of Cardiology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: nc69@le.ac.uk

Introduction

Pathological cardiac remodeling due to sustained mechanical stress, tissue injury and neurohormonal stimulus can lead to hypertrophic growth, cardiomyopathy and heart failure. In order to decipher the complexity of the multiple gene networks that converge to initiate and coordinate such response, essential upstream integral factors need to be identified and characterized. STARS (STriated muscle Activator of Rho Signaling [also known as MS1 (Myocyte Stress 1) and ABRA (Actin-Binding Rho Activating-protein)], is an evolutionarily-conserved sarcomeric actin binding protein that is acutely (and transiently) up-regulated in response to pressure overload left ventricular hypertrophy with a peak expression well before any detectable increase in left ventricular (LV) mass [1], [2]. This suggests a possible role for STARS in the initial signaling of cardiac remodeling such as the hypertrophic response. Sustained over-expression of STARS in

the mouse heart have no effect on LV mass but resulted in an increased sensitivity to hemodynamic stress leading to cardiac hypertrophy and heart failure [3].

STARS expression parallels the development and regression of skeletal muscle hypertrophy in humans [4]. Moreover, STARS can stimulate serum response factor (SRF)-dependent transcription *in cultured cells* by inducing the nuclear accumulation of the SRF co-factors, myocardin-related transcription factors (MRTFs) through a mechanism dependent on RhoA (ras homolog gene family, member A) and actin polymerization [2], [5]. Forced over-expression of STARS *in vitro* results in an increase in cell size, induces expression of several MRTF/SRF target genes and provides protection against apoptosis [6], providing further evidence of its role in striated muscle pathophysiology.

STARS is expressed during embryonic cardiac development [1], [2] and has been implicated as a key factor involved in myogenic differentiation [7]. STARS could play a more widespread role in

muscle pathophysiology such as fluid shear stress induced blood vessel formation (arteriogenesis) [8], insulin resistance and fat metabolism in skeletal muscle [9], [10]. To gain a better understanding on the function and mechanism of STARS in cardiac biology *in vivo*, we investigated the orthologue in zebrafish and report that knockdown of STARS in zebrafish results in severe contractile dysfunction that can be rescued by SRF. We also provide evidence indicating that SRF can regulate *STARS* transcription establishing a newly discovered autoregulatory feed-forward loop for STARS-SRF signaling.

Results

Expression of *zSTARS* in the Zebrafish

The zebrafish *STARS* orthologue (*zSTARS*) contains a high degree of homology to other *STARS* orthologues, particularly in the actin-binding regions critical for signaling from actin to SRF-mediated gene transcription (Figure S1, Text S1). Whole mount *in situ* hybridization was performed in order to investigate the developmental expression pattern of *zSTARS*. *zSTARS* expression was detected in both the atrium and ventricle of the zebrafish heart beginning at 48 hpf (Figure 1A–B). *zSTARS* transcript was also detected in somites by the 16 somite stage (17 hpf) (Figure 1C–E). Other notable embryonic sites of expression include the developing brain (Figure 1D, E), jaw structures, and pectoral fins (data not shown).

Knockdown of *zSTARS* in Zebrafish Leads to Structural and Functional Cardiac Abnormalities

To assess the *in vivo* role of *zSTARS* during cardiac development, we performed morpholino-induced knockdown of *zSTARS* during zebrafish embryonic development. Injection of a morpholino directed against the translation initiation site of *zSTARS* causes a striking cardiovascular phenotype by 48–56 hpf (126 out of 164 embryos, 77%). Morphologically, the heart tube is incompletely looped, causing the atrium and ventricle to retain an immature linear form (Figure 2A and B, Figure S2A and S2B). The atrium is dilated, and overall contractility of both chambers appears impaired (Movie S1, Movie S2). These cardiac abnormalities lead to significant pericardial edema, with congestion and

pooling of blood in the sinus venosus. The most significantly affected embryos show complete absence of circulation despite a beating heart. *zSTARS* morphants also exhibited abnormal somite formation and curvature of the longitudinal axis, suggesting an important developmental role for *zSTARS* in the non-cardiac sites of expression (Figure 2C–E). In contrast, injection of a control morpholino with five mismatches to the *zSTARS* sequence does not cause obvious developmental abnormalities (0 out of 152 embryos; $\chi^2 = 194$, $p < 0.001$) or obstruction of the outflow tract (Figure S2C).

Over-expression of SRF Rescues the Cardiac Phenotype Induced by *zSTARS* Knockdown

We quantified cardiac function and dimensions in *zSTARS* morphants using high-speed video microscopy [11]. In addition to the abnormal morphology of heart development, *zSTARS* knockdown results in a smaller ventricle. Specifically, ventricular end diastolic size is decreased compared to controls. At end systole, the morphant ventricle is unable to contract to the same degree as control ventricles resulting in a larger ventricular end diastolic size (Figure 3A, Figure S3, Movie S1, Movie S2). Together, these changes result in impaired cardiac performance shown by a significant decrease in ventricular fractional shortening compared to control (Figure 3B). Injection of *zsf* mRNA suppresses the cardiac phenotype induced by *zSTARS* knockdown: fractional shortening ($p < 0.05$) and ventricular systolic and diastolic dimensions are restored to values indistinguishable from control embryos (Figure 3, Movie S3).

SRF Regulate *STARS* Transcription via an Autoregulatory Feed-forward Loop

Ectopic over-expression of *STARS* significantly increased the activity of the *STARS* proximal reporter, which contains a conserved SRF binding site (position –305 bp). *In vivo* binding of SRF to this site was confirmed by ChIP (Figure 4). This and similar SRF-chromatin preparations have been used to detect SRF binding to the sodium-calcium exchanger (*NCX1*) gene [12]. The SRF inhibitor CCG-1423, which works by inhibiting MRTF nuclear localization [9], completely blocked *STARS* proximal reporter activity in H9c2 cells. Of interest, over-expression of rat




Figure 1. Whole mount *in situ* expression of *zSTARS* in zebrafish embryos. A. Frontal view of 48 hpf embryo showing *zSTARS* expression in ventricle (v) and atrium (a). B. Schematic depicting position of ventricular (v) and atrium (a) in the view from part A. C. Expression in somites at 16 somite stage (17 hpf). D. and E. Expression in somites and central nervous system at 24 hpf (D) and 48 hpf (E). doi:10.1371/journal.pone.0040966.g001




Figure 2. Developmental phenotype of morpholino-induced knockdown of zSTARS: lateral views of 56 hpf embryos. A. Embryo injected with control morpholino (with 5 mismatches). The cardiac silhouette is demarcated by arrowheads. The heart tube is looped so that the ventricle (v) and atrium (a) are closely apposed (inset). Circulating red blood cells (rbc) are visible in a thin rim along the inferior aspect of the yolk and within the heart. B. Embryo injected with zSTARS morpholino. The heart tube is unlooped so that the ventricle (v) and atrium (a) are co-linear, with atrial dilation (inset). There is significant edema in the pericardium and over the yolk, with stasis of red blood cells (rbc) over the yolk. C. Lateral view of entire 56 hpf embryo following injection of control, mismatch morpholino. D. and E. 56 hpf embryos showing representative phenotypes of zSTARS morpholino injection.

doi:10.1371/journal.pone.0040966.g002

STARS also significantly increased *sfm* mRNA and several MRTF-SRF target genes in H9c2 cells [6], [13].

Discussion

In this study, we isolated the mammalian homologue of *STARS* in zebrafish and examined its role in cardiac function and development. Morpholino knockdown of *STARS* in the zebrafish results in abnormal cardiac looping, an enlarged atrium, and severe contractile dysfunction with resulting marked impaired circulation. These phenotypes confirm an important role for *STARS* in cardiac development and function. Notably, the cardiac phenotype of *zSTARS* knockdown resembles that of a zebrafish morpholino against cardiac troponin T (*tnnt2*), which can be mutated in human hypertrophic cardiomyopathy [14]. Both *zSTARS* and *zTnnt2* knockdown result in enlarged atria, decreased ventricular fractional shortening, and decreased end diastolic dimension. Thus, genes such as *STARS* and *Tnnt2* which regulate hypertrophic response in adults may also play critical roles in cardiac embryonic development. Furthermore, these examples illustrate how studying developmental phenotypes arising from zebrafish knockdown can shed light on physiological mechanisms of cardiac stress response (such as cardiomyopathy and contractility dysfunction).

Previous studies have demonstrated that *STARS* can activate *sf* transcription activity *in vitro* [2], [3]. In the present study, we provide the first *in vivo* evidence that *sf* is an essential downstream

target of *STARS* by showing that injection of *zsf* mRNA rescues cardiac abnormalities caused by morpholino-mediated *zSTARS* knockdown. *SRF* is known to be involved in cardiac development, structure and function [15], [16] and knockdown of *STARS* was shown to reduce *SRF* activity [5]. In addition, it was demonstrated that cardiac-specific deletion of *SRF* in the embryonic heart results in cardiac defects [15] and deletion of *SRF* from the adult heart caused reduced contractility leading to dilated cardiomyopathy [17]. It is conceivable that knockdown of *STARS* decreased *SRF* activity, which resulted in decreased cardiac function. Consistent with this hypothesis, *SRF* expression restored *SRF* activity and rescued the cardiac abnormalities as shown here.

In addition to its effects on cardiac function, *zSTARS* knockdown causes phenotypes consistent with its non-cardiac sites of expression, including abnormal somite formation and curvature and shortening of the longitudinal axis. As the axial skeleton and skeletal muscle are derived from somites [18], this novel finding implies an important role for *STARS* in skeletal muscle development. *STARS* levels were up-regulated in human skeletal hypertrophy and down-regulated in skeletal muscle atrophy [4] and in aged skeletal muscle of mice [19] demonstrating a role for *STARS* in the maintenance of skeletal muscle. Interestingly, the same finding was observed for *SRF* [4], [19] and deletion of *SRF* in mice resulted in impaired muscle growth [20]. Collectively, these results extend the findings in cardiac tissue and suggest that




Figure 3. Ventricular function and dimensions based on quantitative analysis of high-speed video microscopy. A. Ventricular dimensions at end-diastole (black bars) and end-systole (white bars). Conditions are identical to those in part a. Values plotted are mean ($n=4$ embryos) \pm standard deviation. Asterisk (*) denotes statistically significant difference by ANOVA. B. Ventricular fractional shortening observed after injection of: control mismatched morpholino (MM MO), zSTARS morpholino + *srf* mRNA (MO + SRF), *srf* mRNA only (SRF only), or zSTARS morpholino only (MO only). Values plotted are mean ($n=4$ embryos) \pm standard deviation. Asterisk (*) denotes statistically significant difference by ANOVA. doi:10.1371/journal.pone.0040966.g003

the STARS-SRF signalling pathways are similarly involved in skeletal muscle development and function.

The present study demonstrates for the first time that *STARS*-deficient animals display severe abnormalities in cardiac development and function, which were rescued by SRF over-expression. Our study further highlights the importance of sarcomeric proteins in cardiac development and biology [21], [22]. Both *STARS* and SRF play comparable roles in not just establishing and maintaining cardiac physiology but also in skeletal muscle and brain development and function. These findings provide support for a widespread role of the *STARS*-SRF signaling axis in multiple tissues *in vivo*. Understanding the precise mechanism of *STARS* expression and regulation could provide a novel avenue to dissect the initiation process of cardiac dysfunction and heart failure.

Materials and Methods

Zebrafish Experiments

All zebrafish experiments were approved by the Subcommittee on Research Animal Care at Massachusetts General Hospital. The investigation conformed to the *Guide for the Care and Use of Laboratory*

Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). IACUC approval number A3596-01. Zebrafish (AB strain) were raised and maintained using standard protocols.

An antisense morpholino oligonucleotide was designed against the translation initiation site, with the sequence: GCTGTACT-CATGGTGTTTTAATTTG (Gene-Tools, Philomath, OR). Antisense and scrambled morpholinos were injected according to standard procedures [23]. For expression of zebrafish (*z*) SRF, the T7 phage promoter sequence was added to the 5' end of the *zsf* cDNA (Open Biosystems, Huntsville, AL) by PCR; *zsf* mRNA was synthesized by *in vitro* transcription and injected using published methods [11], [23], [24].

Cloning of Zebrafish *STARS* Orthologue (zSTARS)

Comparison of the rat *STARS* sequence with zebrafish sequences identified a homologous EST (AI721847). Primers were designed within this sequence for nested 5' and 3' RACE PCR reactions (SMART RACE, Clontech) on cDNA isolated from 72 hpf (hours post fertilization) zebrafish embryos (Trizol (Invitrogen), according to manufacturer's instructions). 3' RACE PCR primer sequences were as follows: 5'-CGCCGAAGTGTAAC-




Figure 4. Binding of SRF to the *STARS* promoter. A. *STARS* expression activates reporter gene constructs containing the conserved serum response element (SRE). Luciferase activity is shown for two constructs upstream of the *STARS* transcription start site. B. Chromatin immunoprecipitation assays were performed with formaldehyde cross-linked chromatin isolated from feline adult cardiomyocytes. Asterisk (*) denotes PCR primer locations. Immunoprecipitations were performed without primary antibody (No Ab) as a negative control, with anti-SRF antibody. Input DNA is also shown as a positive control. Similar results were observed in four independent experiments. C. The SRF inhibitor CCG-1423 (1 μ M) abolished *STARS* -365/+60 promoter-reporter activity in H9c2 cells (n=3 experiments, in triplicates). doi:10.1371/journal.pone.0040966.g004

GAGTTTGGAAAG-3' and 5'-CACCAATCAACTGACGACT-GAAGACACC-3'. 5' RACE PCR primer sequences were as follows: 5'-GAGCTTCTGGCCCTCCATGTGATCT-3' and 5'-ATCGCTGTTGCTCGCTCAGAGATGCT-3'. Full length coding sequence of *zSTARS* was cloned into pCRIITopo using the TopoTA cloning system (Invitrogen).

In situ Hybridization

Digoxigenin labeled RNA probes were generated by *in vitro* transcription according to manufacturer's instructions (MEGA-script SP6, Ambion). Embryos were fixed at the indicated times in

4% formaldehyde in PBS overnight at 4°C, and transferred to methanol for storage at -20°C. *In situ* hybridization on whole mount embryos was performed as previously described [11].

Antisense Morpholino Injection

An antisense morpholino oligonucleotide was designed against the translation initiation site, with the sequence: GCTGTACT-CATGGTGTTTTAATTTG (Gene-Tools). A control morpholino with 5 mismatches was also designed: GCTcTACT-gATGcTGTTTaAATaTG. Morpholinos were dissolved in Danieau's buffer according to manufacturer's instructions at

a concentration of 300 μM , and injected into embryos at the 1 cell stage [23].

RNA Injection

The T7 phage promoter sequence was added to the 5' end of the cDNA encoding *zsf* (Open Biosystems, Huntsville, AL) by PCR. This template was used to synthesize capped mRNA encoding the full-length coding sequence of *sf* by *in vitro* transcription (mMessage Machine, Ambion). mRNA was diluted in Danieau's buffer to a final concentration of 100 ng/ μL and co-injected with morpholino (at 400 μM) as above. $n=4$ for each condition.

Ventricular Function Measurements and M-mode Recordings

Extensive description on the measurement of cardiovascular function and the creation of m-mode images have been published elsewhere. Ventricular size and fractional shortening were measured as previously described [24].

STARS Promoter-reporter Transfection Assays and mRNA Analysis

The rat *STARS*-1585/+60-Luc reporter was generated as described elsewhere [7]. For the -365/+60 region, the rat *STARS* 5'-upstream region was PCR-amplified using primers -365-MluI-Forward: 5'-GTACGCGTTACAGAGGTTTAAGTGAGAGC - 3' and +60-BglII-Reverse: 5'-CCAGATCTCAGGC-TACCTGTTTCTTCTC-3', gel-purified and cloned into pGEMTEasy vector (Promega). This plasmid was subsequently restriction digested by *MluI* and *BglII* and the insert was gel-purified and subcloned directionally into the pGL3-Promoter Luc vector (Promega). The *STARS*-365/+60 Luc reporter was sequenced for authenticity.

Transfection of *STARS* Luciferase reporters were done as described [7]. Briefly, 0.5 μg of *STARS* reporter plasmids (or its empty control vector pGL3-promoter) and 10 ng of Renilla reporter was cotransfected into H9c2 cells (60% confluency) in 24-well plates using the JetPei reagent (Source BioScience). For standard transfection, cell extracts were measured for activity after 48 h using a Dual-Luciferase Assay kit (Promega). For SRF inhibition experiments, CCG-1423 (1 μM ; Sigma) was added 24 h post-transfection and left for a further 24 h before assayed.

Chromatin Immunoprecipitation (ChIP)

The feline cardiomyocyte chromatin was a gift from Dr DL Menick [12], [25] obtained using the Santa Cruz SRF G-20 antibody (sc-335). The feline *STARS* proximal promoter was PCR

amplified from the immunoprecipitated and non-immunoprecipitated chromatin (negative control) using the following primers: *STARS*-PP-Fw Sense: 5'-CGGAGCTCAGAACACCGTCA-GAGCCATAGC-3', and *STARS*-PP-Rv Antisense- 5'-CCAAGCTTCAGGCTACCTGTTTCTTCTC-3'. The input DNA was used as the positive control.

Statistical Analysis

Data are presented as mean \pm SEM. Data were analyzed by ANOVA followed by Bonferroni post hoc testing (Graph Pad Prism, La Jolla, CA).

Supporting Information

Figure S1 Amino acid alignment of human, mouse, rat and zebrafish STARS.

(DOC)

Figure S2 Tg(FLK:G-RFP) embryos were injected with MO at the 1 cell stage and allowed to develop under standard conditions.

(DOC)

Figure S3 M-mode images of zebrafish ventricles.

(DOC)

Movie S1 Cardiac ventricular function of control mismatched *zSTARS* morphants.

(MOV)

Movie S2 Ventricular function of *STARS* morphants.

(MOV)

Movie S3 Ventricular function of *zSTARS* morpholino with *zsf* mRNA.

(MPG)

Text S1

(DOC)

Acknowledgments

The authors would like to thank Dr Donald L. Menick for the gift of the feline cardiac SRF-chromatin samples and Patricia A. Collins for injecting some of the embryos and image analysis.

Author Contributions

Conceived and designed the experiments: NJS SYS JTS NWC. Performed the experiments: SYS JTS NWC SO. Analyzed the data: SYS JTS NWC SO ALK. Wrote the paper: NWC ALK JTS SYS.

References

- Mahadeva H, Brooks G, Lodwick D, Chong NW, Samani NJ (2002) *ms1*, a novel stress-responsive, muscle-specific gene that is up-regulated in the early stages of pressure overload-induced left ventricular hypertrophy. *FEBS Lett* 521: 100–104.
- Arai A, Spencer JA, Olson EN (2002) STARS, a striated muscle activator of Rho signaling and serum response factor-dependent transcription. *J Biol Chem* 277: 24453–24459.
- Kuwahara K, Pipes GC, McAnally J, Richardson JA, Hill JA, et al. (2007) Modulation of adverse cardiac remodeling by STARS, a mediator of MEF2 signaling and SRF activity. *J Clin Invest* 117: 1324–1334.
- Lamon S, Wallace MA, Leger B, Russell AP (2009) Regulation of STARS and its downstream targets suggest a novel pathway involved in human skeletal muscle hypertrophy and atrophy. *J Physiol* 587: 1795–1803.
- Kuwahara K, Barrientos T, Pipes GC, Li S, Olson EN (2005) Muscle-specific signaling mechanism that links actin dynamics to serum response factor. *Mol Cell Biol* 25: 3173–3178.
- Koekemoer AL, Chong NW, Goodall AH, Samani NJ (2009) Myocyte stress 1 plays an important role in cellular hypertrophy and protection against apoptosis. *FEBS Lett* 583: 2964–2967.
- Ounzain S, Dacwag CS, Samani NJ, Imbalzano AN, Chong NW (2008) Comparative in silico analysis identifies bona fide MyoD binding sites within the Myocyte stress 1 gene promoter. *BMC Mol Biol* 9: 50.
- Troidl K, Ruding I, Cai WJ, Mucke Y, Grosseckler L, et al. (2009) Actin-Binding Rho Activating Protein (Abra) Is Essential for Fluid Shear Stress-Induced Arteriogenesis. *Arterioscler Thromb Vasc Biol* 29: 20932101.
- Jin W, Goldfine AB, Boes T, Henry RR, Ciaraldi TP, et al. (2011) Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. *J Clin Sci* 121: 918–929.
- Wallace MA, Hock MB, Hazen BC, Kralli A, Snow RJ, et al. (2011) Striated muscle activator of Rho signalling (STARS) is a PGC-1 α /oestrogen-related receptor- α target gene and is upregulated in human skeletal muscle after endurance exercise. *J Physiol* 15: 2027–2039.

11. Thisse C, Thisse B, Schilling T F, Postlethwait JH (1993) Structure of the zebrafish snail1 gene and its expression in wild-type, spadetail and no tail mutant embryos. *Development* 119: 1203–1215.
12. Xu L, Renaud L, Müller JG, Baicu CF, Bonnema DD, et al. (2006) Regulation of Ncx1 expression. Identification of regulatory elements mediating cardiac-specific expression and up-regulation. *J Biol Chem* 281: 34430–34440.
13. Chong NW, Koekemoer AL, Samani NJ (2005) Over-expression of myocyte stress 1 protein *in vitro* switches on the fetal gene programme and anti-apoptotic pathways. *Heart* 91: A44.
14. Becker JR, Deo RC, Werdich AA, Panáková D, Coy S, et al. (2011) Human cardiomyopathy mutations induce myocyte hyperplasia and activate hypertrophic pathways during cardiogenesis in zebrafish. *Dis Model Mech.* 4: 400–410.
15. Miano JM, Ramanan N, Georger MA, Mesy Bentley KL, Emerson RL (2004) Restricted inactivation of serum response factor to the cardiovascular system. *Proc Natl Acad Sci U S A* 101: 17132–17137.
16. Niu Z, Yu W, Zhang SX, Barron M, Belaguli NS, et al. (2005) Conditional mutagenesis of the murine serum response factor gene blocks cardiogenesis and the transcription of downstream gene targets. *J Biol Chem* 280: 32531–32538.
17. Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkenin JD, et al. (2005) Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. *Circulation* 112: 2930–2939.
18. Stickney HL, Barresi MJ, Devoto SH (2000) Somite development in zebrafish. *Dev Dyn* 219: 287–303.
19. Sakuma K, Akiho M, Nakashima H, Akima H, Yasuhara M (2008) Age-related reductions in expression of serum response factor and myocardin-related transcription factor A in mouse skeletal muscles. *Biochim Biophys Acta* 1782: 453–461.
20. Li S, Czubryt MP, McAnally J, Bassel-Duby R, Richardson JA, et al. (2005) Requirement for serum response factor for skeletal muscle growth and maturation revealed by tissue-specific gene deletion in mice. *Proc Natl Acad Sci U S A* 102: 1082–1087.
21. Dowling JJ, Gibbs E, Russell M, Goldman D, Minarcik J, et al (2008) Kindlin-2 is an essential component of intercalated discs and is required for vertebrate cardiac structure and function. *Circ Res.* 102: 423–431.
22. Morimoto S (2008) Sarcomeric proteins and inherited cardiomyopathies. *Cardiovasc Res.* 77: 659–666.
23. Nasevicius A, Ekker SC (2000) Effective targeted gene ‘knockdown’ in zebrafish. *Nat Genet.* 26: 216–220.
24. Shin JT, Pomerantsev EV, Mably JD, MacRae CA (2010) High-resolution cardiovascular function confirms functional orthology of myocardial contractility pathways in zebrafish. *Physiol Genomics.* 42: 300–309.
25. Chandrasekaran S, Peterson RE, Mani SK, Addy B, Buchholz AL (2009) Histone Deacetylases Facilitate Sodium/Calcium Exchanger Upregulation in Adult Cardiomyocytes. *FASEB J* 11: 3851–64.